AbClon Partnership: Revolutionizing Cancer and Autoimmune Therapies
TCT Sağlık Teknolojileri is thrilled to collaborate with AbClon, a pioneering biotech company specializing in innovative therapies for cancer and autoimmune diseases. This strategic partnership aligns with TCT’s vision to bring advanced treatment options to Turkey, enabling local access to cutting-edge solutions from AbClon’s robust pipeline. Below is an overview of the transformative therapies developed by AbClon:
AC101: Redefining HER2-Positive Cancer Treatment
AC101 is a groundbreaking monoclonal antibody targeting HER2-positive metastatic gastric cancer. Developed in collaboration with Henlius Biotech, AC101 offers a significant advancement over existing therapies such as Trastuzumab. By targeting a specific epitope in domain IV of HER2, AC101 delivers superior efficacy. Currently in Phase II clinical trials, it demonstrates the potential to replace standard first-line therapies for advanced gastric and gastroesophageal cancers, setting a new benchmark for HER2-positive cancer treatment.
AT101: Next-Generation CD19 CAR-T Therapy
AT101 is AbClon’s revolutionary CAR-T therapy for CD19-positive B-cell malignancies, such as Diffuse Large B-Cell Lymphoma (DLBCL). Addressing the challenges of earlier CAR-T therapies, AT101 uses a novel epitope and humanized antibody to reduce immunogenicity and improve durability. Phase I trials have shown exceptional results, with a 100% complete response rate at higher dose levels. With ongoing Phase II trials, AT101 is poised to become a global leader in CAR-T therapies.
zCAR-T Platform: Switchable CAR-T Technology
The zCAR-T platform is a breakthrough in CAR-T innovation, offering the ability to toggle CAR-T cells on and off, providing better control over immune responses. This platform is designed to expand CAR-T applications into solid tumors, overcoming current limitations. A key candidate, AT501, targets HER2-positive solid tumors and shows promise in preclinical models. This platform holds the potential to redefine CAR-T therapy across both hematologic and solid cancers.
AffiMab Bispecific Antibodies: Dual-Targeting Cancer Therapies
AbClon’s AffiMab platform develops bispecific antibodies that engage two cancer pathways simultaneously, enhancing immune response and tumor targeting.
Key candidates include:
- AM105 (EGFR/4-1BB): Targeting metastatic colorectal cancer, it combines EGFR inhibition with immune stimulation.
- AM109 (PSMA/4-1BB): Designed for metastatic castration-resistant prostate cancer (mCRPC), this therapy improves treatment for challenging prostate cancers.
These bispecific antibodies offer new hope for patients with resistant cancers and are poised to significantly impact global oncology care.
AT601: Innovative CD30 CAR-T Therapy
AT601 targets CD30-positive lymphomas, leveraging gene-editing technologies like BTLA knockout to enhance CAR-T efficacy in challenging tumor microenvironments. Currently in early-stage development, AT601 represents a promising addition to AbClon’s pipeline.
Driving Innovation in Turkey with AbClon
By partnering with AbClon, TCT is advancing the local production and delivery of innovative therapies, ensuring that patients in Turkey benefit from these life-saving treatments. Together, TCT and AbClon aim to transform the landscape of oncology and autoimmune disease treatment, paving the way for a healthier future in Turkey and beyond.